Anika Therapeutics [ANIK] vs Zoetis [ZTS] Detailed Stock Comparison

Anika Therapeutics Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Anika Therapeutics Inc. wins in 6 metrics, Zoetis Inc. wins in 13 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Anika Therapeutics Inc. Zoetis Inc. Better
P/E Ratio (TTM) N/A 19.58 N/A
Price-to-Book Ratio 1.48 15.04 Anika Therapeutics Inc.
Debt-to-Equity Ratio 18.30 279.59 Anika Therapeutics Inc.
PEG Ratio 38.33 2.81 Zoetis Inc.
EV/EBITDA -32.06 13.96 Zoetis Inc.
Profit Margin (TTM) -9.64% 28.24% Zoetis Inc.
Operating Margin (TTM) 2.11% 34.69% Zoetis Inc.
EBITDA Margin (TTM) 2.11% 34.69% Zoetis Inc.
Return on Equity -6.71% 65.99% Zoetis Inc.
Return on Assets (TTM) -3.52% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $4.36M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 30.31% -53.93% Anika Therapeutics Inc.
Price-to-Sales Ratio (TTM) 1.96 5.26 Anika Therapeutics Inc.
Enterprise Value $175.41M $56.75B Zoetis Inc.
EV/Revenue Ratio 1.56 6.00 Anika Therapeutics Inc.
Gross Profit Margin (TTM) 62.65% 70.17% Zoetis Inc.
Revenue per Share (TTM) $8 $21 Zoetis Inc.
Earnings per Share (Diluted) $-0.70 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.28 0.97 Anika Therapeutics Inc.
Short % of Float 6.11% 4.06% Zoetis Inc.

Anika Therapeutics Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

ANIK
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Anika Therapeutics Inc.0.21%-3.43%-1.17%0.42%52.49%53.80%
Zoetis Inc.1.51%-4.46%-31.75%-39.76%-38.95%-38.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Anika Therapeutics Inc.30.31%-46.72%-68.39%-69.40%100.97%23.55%
Zoetis Inc.-53.93%-54.80%-55.66%62.09%150.53%150.53%

Performance & Financial Health Analysis: Anika Therapeutics Inc. vs Zoetis Inc.

MetricANIKZTS
Market Information
Market Cap i$221.65M$49.75B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i104,9652,727,710
90 Day Avg. Volume i117,5523,835,940
Last Close$14.41$167.10
52 Week Range$7.87 - $16.24$139.70 - $200.33
% from 52W High-11.27%-16.59%
All-Time High$75.72 (Oct 21, 2019)$249.27 (Dec 27, 2021)
% from All-Time High-80.97%-32.96%
Growth Metrics
Quarterly Revenue Growth0.10%0.03%
Quarterly Earnings Growth-24.73%0.04%
Financial Health
Profit Margin (TTM) i-0.10%0.28%
Operating Margin (TTM) i0.02%0.35%
Return on Equity (TTM) i-0.07%0.66%
Debt to Equity (MRQ) i18.30279.59
Cash & Liquidity
Book Value per Share (MRQ)$10.33$7.84
Cash per Share (MRQ)$4.29$5.48
Operating Cash Flow (TTM) i$11.19M$2.90B
Levered Free Cash Flow (TTM) i$13.28M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Anika Therapeutics Inc. vs Zoetis Inc.

MetricANIK (Apr 26, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) iN/A19.58
Forward P/E i38.3315.61
PEG Ratio i38.332.81
Price to Sales (TTM) i1.965.26
Price to Book (MRQ) i1.4815.04
Market Capitalization
Market Capitalization i$221.65M$49.75B
Enterprise Value i$175.41M$56.75B
Enterprise Value Metrics
Enterprise to Revenue i1.566.00
Enterprise to EBITDA i-32.0613.96
Risk & Other Metrics
Beta i0.280.97
Book Value per Share (MRQ) i$10.33$7.84

Financial Statements Comparison: Anika Therapeutics Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricANIK (2025)ZTS (2025)
Revenue/Sales i112.82M9.47B
Cost of Goods Sold i49.01M2.67B
COGS % of Revenue i43.4%28.2%
Gross Profit i63.81M6.80B
Gross Margin i56.6%71.8%
Research & Development i25.77M698.00M
Operating Income (EBIT) i-11.05M3.60B
Operating Margin i-9.8%38.0%
EBITDA i-5.32M4.17B
EBITDA Margin i-4.7%44.1%
Pre-Tax Income i-9.31M3.36B
Pre-Tax Income % of Revenue i-8.2%35.5%
Income Tax i672,000687.00M
Income Tax % of Revenue i0.6%7.3%
Net Income (Profit) i-10.88M2.67B
Profit Margin i-9.6%28.2%

Balance Sheet & Liquidity Metrics

MetricANIK (2025)ZTS (2025)
Cash & Equivalents i57.48M2.31B
Total Current Assets i103.36M6.77B
Total Current Assets % of Revenue i91.6%71.5%
Total Current Liabilities i21.91M2.24B
Total Current Liabilities % of Revenue i19.4%23.6%
Long-Term Debt i24.20M9.24B
Long-Term Debt % of Revenue i21.4%97.6%
Total Shareholders Equity i143.47M3.33B
Retained Earnings i60.79M13.74B
Retained Earnings % of Revenue i53.9%145.2%
Property, Plant & Equipment i75.44M288.00M

Cash Flow Statement Comparison

MetricANIK (2025)ZTS (2025)
Operating Cash Flow i4.44M2.78B
Operating Cash Flow % of Revenue i3.9%29.3%
Capital Expenditures i-6.83MN/A
Free Cash Flow i4.36M2.28B
FCF Margin i3.9%24.1%
Debt Repayment iN/A-1.35B
Common Stock Repurchase i-9.49M-3.24B

Short Interest & Institutional Ownership Analysis

MetricANIKZTS
Shares Short i688,32515.12M
Short Ratio i5.323.60
Short % of Float i6.11%4.06%
Shares Outstanding i13.89M424.93M
Float Shares i11.35M421.29M
% Held by Insiders i5.41%0.15%
% Held by Institutions i92.74%101.50%
% Held by Public i1.85%-1.65%

Dividend Analysis & Yield Comparison: Anika Therapeutics Inc. vs Zoetis Inc.

MetricANIKZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026